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Many soluble factors are involved in tumor angiogenesis. Thus, it is valuable to
identify novel soluble factors for effective control of tumor angiogenesis in gas-
tric cancer (GC). We investigated the role of extracellular high-mobility group
box-1 (HMGB1) and its associated soluble factors in the tumor angiogenesis of
GC. Clinically, we measured serum levels of HMGB1 and GC-associated cytokines/
chemokines using GC serum samples (n = 120), and calculated microvessel density
(MVD) by CD34 immunostaining using human GC tissues (n = 27). Then we ana-
lyzed the correlation of serum HMGB1 levels with MVD or that with cytokine/
chemokine levels by linear regression. As in vitro angiogenesis assay for HMGB1,
HUVEC migration and capillary tube formation assay were carried out using dif-
ferent histological types of human GC cells (N87 and KATOIII). CD34-positive
microvessels were detected from early GC, but MVD increased according to GC
stages, and were closely correlated with serum HMGB1 levels (R = 0.608,
P = 0.01). The HUVECs cultured in conditioned media derived from rhHMGB1-trea-
ted or HMGB1-TF GC cells showed remarkably enhanced migration and tube for-
mation activities. These effects were abrogated by anti-HMGB1 antibody or
HMGB1 siRNA in both N87 and KATOIII cells (all P < 0.05). Among tested cytoki-
nes/chemokines, interleukin-8 (IL-8) was the most remarkable cytokine correlated
with serum HMGB1 (P < 0.001), and enhanced HUVEC migration and tube forma-
tion activities by rhHMGB1 or HMGB1-TF were significantly reversed by IL-8 inhi-
bition. These results indicate overexpressed HMGB1 contributes to tumor
angiogenesis through IL-8 mediation, and combined targeting of HMGB1 and IL-8
can control tumor angiogenesis in GC.
G astric cancer remains the second leading cause of cancer-related mortality worldwide, even though its incidence
has decreased over the past century.(1,2) The overall 5-year sur-
vival rate of GC is approximately 20% because AGC is associ-
ated with high rates of recurrence and metastasis,(2) even after
radical resection and aggressive perioperative or adjuvant
treatment.(3)
Metastasis is a multistage process involving cancer emigra-
tion/invasion, intravasation, circulation, extravasation, and
establishment at new sites. Tumor angiogenesis plays a critical
role during this multistage process of metastasis in many solid
cancers;(4,5) tumor angiogenesis facilitates cancer cells to
easily access into blood circulation by providing adequate
blood vessel supply. In the complex regulation of angiogene-
sis, many pro-angiogenic factors are involved.(6–8) Therefore,
tumor angiogenesis and its associated soluble factors are
highly relevant targets for controlling the metastasis of many
solid tumors. Recent studies have shown that tumor-derived
angiogenic factors are closely associated with hematogenous
metastasis and poor prognosis of many cancers,(6–8) and phar-
macologic blockade of angiogenesis by inhibiting these soluble
pro-angiogenic factors is a promising strategy for decreasing
cancer recurrence and metastasis.(9,10)
A group of molecules that may act as mediators of angiogene-
sis are the so-called high-mobility group proteins. High-mobility
group box-1, known as a pro-inflammatory cytokine, is an
important member of the high-mobility group superfamily.
It plays an important role in angiogenesis in various situa-
tions.(11–14) Recently, many studies have reported that overex-
pressed HMGB1 is involved in tumor development and
metastasis through its ability to mediate tumor-associated
inflammation, to promote cell migration and to promote angio-
genesis.(15–18) High-mobility group box-1 is overexpressed in
approximately 85% of GCs, and high levels of serum HMGB1
are associated with advanced stage and poor prognosis of
GC.(19,20) Because HMGB1 is also a potent soluble angiogenic
factor in solid tumors,(17,18) extracellular HMGB1 overexpres-
sion may contribute to tumor angiogenesis in GC. However, the
role of HMGB1 in tumor angiogenesis in GC remains unclear.
In the present study, we investigated the role of extracellular
HMGB1 in tumor angiogenesis and determined its associated
soluble factors in GC.
Cancer Sci | August 2017 | vol. 108 | no. 8 | 1594–1601 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attrib
ution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for
commercial purposes.
Materials and Methods
Cell lines and culture. In the current study, we used NCI-N87
cells as a gastric adenocarcinoma cell line and KATOIII cells as
a gastric signet-ring cell carcinoma cell line. These two different
types of human GC cells (Korean Cell Line Bank, Seoul, Korea)
were cultured in RPMI-1640 (Gibco-Invitrogen, Grand Island,
NY, USA) supplemented with 10% FBS) (Gibco-Invitrogen)
and 1% antibiotics (100 U/mL penicillin G and 100 lg/mL
streptomycin; Gibco-Invitrogen) in mycoplasma-free systems
under a humidified atmosphere with 5% CO2 at 37°C.
Primary HUVECs were purchased from Lonza (Basel,
Switzerland) and cultured in endothelial cell growth medium
(Lonza) under equivalent conditions to those of GC cells. All
cells used in experiments underwent fewer than eight passages
after resuscitation. The identity and uniqueness of cell lines
were confirmed by DNA fingerprinting analyses with short tan-
dem repeat markers.
Clinical sample collection. Serum samples were obtained from
a total of 120 GC patients; 40 samples from patients with
EGC, 40 samples from patients with AGC-M0 and 40 samples
from patients with AGC-M1 at Yonsei University Health Sys-
tem (Seoul, Korea). All disease entities were histologically
confirmed. Among 120 GC patients, 27 patients (10 EGC, 10
AGC-M0, and 7 AGC-M1) were selected to obtain tissue sam-
ples. Gastric cancer stage was analyzed according to the Amer-
ican Joint Committee on Cancer’s TNM staging classification
for GC. Clinical sampling was approved by the Institutional
Review Board of the Yonsei University Health System for
human projects according to the principles of the Helsinki
Declaration (No. 4-2011-0609), and written informed consent
was obtained. Patients with other chronic diseases or cancers
were excluded. Blood samples were collected before any treat-
ment and stored at 80°C as serum fractions until analysis.
Reagents. Human recombinant HMGB1 protein was
purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-
HMGB1 chicken IgY neutralizing polyclonal antibody (anti-
HMGB1 Ab) was purchased from Shino-Test (Tokyo, Japan)
and anti-chicken IgY for control (control Ab) was purchased
from Abcam (Cambridge, UK).
Plasmids and siRNA. Gastric cancer cell lines were trans-
fected with 1 lg pCMV-SPORT6-HMGB1 plasmid (Korea
Research Institute of Bioscience and Biotechnology, Daejeon,
Korea) or 1 lg pCMV-SPORT6 vector (Mock; Invitrogen) in
a 24-well culture plate using Lipofectamine LTX and Plus
Reagent (Invitrogen). Gastric cancer cell lines were transfected
with 0.5 lg control siRNA or siRNA targeting HMGB1 or
IL-8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in a
24-well culture plate using TransPass R2 Transfection Reagent
(New England Biolabs, Ipswich, MA, USA).
Enzyme-linked immunosorbent assay and chemiluminescent
immunoassay. Serum HMGB1 levels were measured using the
commercially available HMGB1 ELISA Kit II (Shino-Test
Corporation, Kanagawa, Japan) according to the manufac-
turer’s instructions. For evaluating the soluble factors associ-
ated with HMGB1-induced angiogenesis in GC, serum levels
of 20 different cytokines or chemokines, which are known to
be involved in GC progression, were measured by chemilumi-
nescent immunoassay using the commercially available
MILLIPLEX MAP Human Cytokine/Chemokine Kit (HCYT-
MAG60PMX29BK; Millipore, Billerica, MA, USA). Tested
cytokines or chemokines included IL-1a, IL-1b, IL-1 receptor
antagonist, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15,
IL-17, interferon-c-induced protein 10, monocyte chemotactic
protein-1, VEGF, tumor necrosis factor-a, Eotaxin-1, macro-
phage inflammatory protein-1a and -1b, and epidermal growth
factor.
Evaluation of MVD by CD34 immunohistochemical staining. To
evaluate the contribution of HMGB1 to tumor angiogenesis in
GC tissues clinically, MVD was calculated in tumor sections
by quantification of CD34-positive vessels. Briefly, rehydrated
paraffin blocks of GC tissue were retrieved using microwaves,
and incubated with primary antibody against CD34 (mouse
1:100; Santa Cruz Biotechnology) at 4°C overnight. Immuno-
histochemical staining was undertaken using the Envision+
system (Dako, Glostrup, Denmark) and counterstained with
hematoxylin solution (Merck, Kenilworth, NJ, USA).
The microvessels stained by CD34 were assessed by light
microscopy in areas of the tumor section containing highest
vascular density (vascular hot spot). The highly vascular areas
were identified by scanning tumor sections at low power field
(940 and then 9100 magnification). After five areas of highest
neovascularization were identified, CD34-positive vessels was
manually counted at 9200 magnification.(21)
Microvessel density was determined as the average counts
of the five fields. Each slide was analyzed by two independent
investigators, who were blinded to knowledge of HMGB1
expression, histopathological characteristics of tumors, and
characteristics of GC patients.
Preparation of CM for evaluation of tumor angiogenesis
in vitro. For preparation of CM, GC cells (N87 or KATO-III)
were cultured in RPMI-1640 supplemented with 1% FBS alone
until 30% cell confluence, then cultured in RPMI-1640 supple-
mented with 1% FBS and rhHMGB1 (10 g/mL), 1% FBS and
rhHMGB1/control Ab, or 1% FBS and rhHMGB1/anti-
HMGB1 Ab (60 lg/mL) for 72 h. The culture media were col-
lected, centrifuged at 350 g, and the supernatants were
obtained. Samples were frozen at 20°C until used. Samples
from three independent cell cultures were pooled. Control
media were collected from supernatants of GC cells cultured
in RPMI-1640 supplemented with 1% FBS alone for 72 h
without any treatment. Protein contents in CM were evaluated
using bicinchoninic acid assay (BCA protein assay kit; Thermo
Fisher Scientific, Waltham, MA, USA).
Similarly, mock-transfected GC cells, HMGB1-TF GC cells,
HMGB1-TF with control-siRNA-treated GC cells, and
HMGB1-TF with HMGB1-siRNA-treated GC cells were cul-
tured in RPMI-1640 supplemented with 1% FBS for 72 h. The
culture media were collected and centrifuged at 350 g, and
then the supernatants were obtained. Samples were frozen at
20°C until used. Samples from three independent cell cul-
tures were pooled.
Endothelial cell migration and capillary tube formation assays.
The endothelial cell migration assay and the capillary tube for-
mation assay are widely used common methods for studying
angiogenesis in vitro.(22) Thus, we carried out HUVEC migra-
tion assays and capillary tube formation assays to evaluate
HMGB1-induced angiogenesis in vitro.
The HUVEC migration assay was undertaken using the BD
BioCoat Angiogenesis System: Endothelial Cell Migration kit
(BD Biosciences). For pretreatment, HUVECs were cultured in
EBM-2 Basal Medium (Lonza) contained no growth factors or
supplements for 24 h to exclude the effect of growth factor in
EBM-2. After pretreatment, HUVECs were seeded (5 9 104
cells) on the upper chamber of the insert and incubated in
50 mL CM, which was contained in each of the bottom wells
as a chemoattractant to HUVECs. After incubation (24 h),
cells on the lower side of the insert were fixed, stained with
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2 lM calcein AM for 30 min, and counted. The migration
indices were calculated as the mean number of cells in three
random fields using DP controller software with an IX71
microscope (9100 magnification; Olympus Corporation,
Tokyo, Japan).
In vitro capillary tube formation assay was carried out using
a Cultrex In Vitro Angiogenesis Assay Tube Formation Kit
(Travigen, Gaithersburg, MD, USA). Growth factor-reduced
basal membrane extract was added to each well of a 96-well
plate and allowed to be polymerized for 1 h at 37°C. Pre-
treated HUVECs were seeded (2 9 104 cells) in each well and
incubated in 50 mL CM for 24 h. After incubation, cells were
stained with 2 lM calcein AM for 30 min and capillary tube
formation was quantified by measuring the number of com-
plete capillary-like hollow lumina using the DP controller soft-
ware with an IX71 microscope (940 magnification; Olympus
Corporation). At least three fields per well were examined, and
each experimental condition was tested in triplicate.
Statistical analysis. Serum levels of HMGB1 and cytokines/
chemokines were expressed as mean values. To compare aver-
ages among three groups, one-way ANOVA with the Bonferroni
multiple comparison was used. To compare values between two
groups, Student’s t-test (two-tailed) was used. Linear regression
analysis was used to evaluate the correlation between serum
levels of HMGB1 and MVD, or the correlations between serum
levels of HMGB1 and cytokines/chemokines.
All statistical analyses were carried out with IBM SPSS
Statistics 23.0 and P-values < 0.05 were considered statisti-
cally significant.
Results
Clinical evidence of HMGB1 involvement in tumor angiogenesis
of GC. To evaluate the involvement of extracellular HMGB1 in
tumor angiogenesis of GC clinically, we used immunohisto-
chemical staining for CD34 in 27 human GC tissue samples
and calculated the number of CD34-positive microvessels in
the tumor area. We then compared the CD34-positive MVD
according to GC stage (Fig. 1). We also analyzed the correla-
tion between serum HMGB1 levels and MVD by performing
linear regression analysis (Fig. 2).
CD34-positive microvessels were detected in all the stages
of GC, especially within the tumor parenchyma and intertu-
moral septa (Fig. 1). However, MVD differed remarkably
according to GC stage (Fig. 1); the calculated mean MVD was
29.6  20.9 vessels/field in EGC, whereas the mean MVD
was 82.5  35.75 vessels/field in AGC-M0, and 87.0  30.87
vessels/field in AGC-M1 (ANOVA, P < 0.001). That is, the
mean MVD was higher in tumor tissues isolated from AGC-
M0 and AGC-M1 than in those isolated from EGC (Fig. 1),
although there was no significant difference between AGC-M0
and AGC-M1 (Bonferroni multiple comparison, P > 0.05).
These results imply that tumor angiogenesis starts from EGC
and progresses actively from AGC-M0 before the establish-
ment of macroscopic metastasis.
Interestingly, immunohistochemical staining showed that the
calculated mean MVD increased with an increase in serum
HMGB1 levels (Fig. 2a). Linear regression analysis validated
the results of immunohistochemical staining; serum HMGB1
levels were closely correlated with MVD in GC tissue (linear
regression, R = 0.608, P = 0.01; Fig. 2b). These results imply
that extracellular HMGB1 contributes to tumor angiogenesis of
GC.
In vitro evidence of HMGB1 involvement in tumor angiogenesis
of GC. To confirm the involvement of HMGB1 in tumor angio-
genesis of GC in vitro, we carried out in vitro angiogenesis
experiments using GC cell lines. First, we used the in vitro
HUVEC migration assay. Figure 3(a) shows that the migration
activity of HUVECs cultured in CM derived from rhHMGB1-
treated N87 cells was higher than that of HUVECs cultured in
CM derived from rhHMGB1-untreated N87 cells (P = 0.004).
This effect of rhHMGB1 was dramatically reversed by addi-
tion of anti-HMGB1 Ab treatment (P = 0.006; Fig. 3a). Simi-
lar results were obtained from HUVECs cultured in CM
derived from KATOIII cells (P < 0.05 for all; Fig. 3b). The
HUVECs cultured in CM derived from HMGB1-TF N87 cells
also showed increased migration activity compared to
HUVECs cultured in CM derived from mock-TF cells
(P = 0.006; Fig. 3c). This increase in migration activity by
HMGB1-TF was reversed after siRNA-mediated inhibition of
HMGB1 (P = 0.008; Fig. 3c). Similar results were obtained
from HUVECs cultured in CM derived from KATOIII cells
(P < 0.05 for all; Fig. 3d).
Next, we carried out the in vitro HUVEC capillary tube for-
mation assay. Figure 4(a) shows that HUVECs cultured in CM
derived from rhHMGB1-treated N87 and KATOIII cells mark-
edly produced capillary-like tubes compared with HUVECs
cultured in CM derived from rhHMGB1-untreated N87 and
KATOIII cells (P < 0.05 for all). This effect of rhHMGB1
was reversed by addition of anti-HMGB1 Ab treatment, which
was consistent with the results of the HUVEC migration assay
in both N87 and KATOIII cells (P < 0.05 for all; Fig. 4a,c).
Fig. 1. CD34 immunohistochemical staining for microvessels in gastric cancer (GC) tumor sections (tumor angiogenesis) according to GC stage.
(a) CD34-positive microvessels in early GC (EGC); serum high-mobility group box-1 (sHMGB1) level, 7.7 ng/mL. (b) CD34-positive microvessels in
locally advanced GC (AGC-M0); sHMGB1 level, 34.1 ng/mL. (c) CD34-positive microvessels in highly advanced GC with metastasis (AGC-M1);
sHMGB1 level, 30.7 ng/mL. Microvessel density (MVD) was determined as the average count of the five fields. Scale bar = 100 lm. Magnification,
9200 by light microscopy.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Fig. 2. Correlation of serum high-mobility group box-1 (sHMGB1) levels with microvessel density (MVD), as determined by quantifying CD34-
positive microvessels in gastric cancer tumor sections. (a) Results of immunohistochemical staining for determining MVD according to sHMGB1
levels. Scale bar = 100 lm. (b) Linear regression analysis to determine the correlation of sHMGB1 levels with MVD. Magnification, 9200 by light
microscopy.
Fig. 3. In vitro angiogenesis assay in gastric cancer cell lines: HUVEC migration assay. (a) Migratory activity of HUVECs cultured in conditioned
media (CM) derived from N87 cells without treatment, or treated with 10 lg/mL recombinant human high-mobility group box-1 (rhHMGB1), or
10 lg/mL rhHMGB1 plus 60 lg/mL anti-HMGB1 antibody for 24 h. (b) Migratory activity of HUVECs cultured in CM derived from untreated,
rhHMGB1-treated, and rhHMGB1 plus anti-HMGB1 Ab-treated KATOIII cells for 24 h. (c) Migratory activity of HUVECs cultured in CM derived
from mock-transfected (TF), HMGB1-TF, and HMGB1-TF plus HMGB1 siRNA-treated N87 cells for 24 h. (d) Migratory activity of HUVECs cultured
in CM derived from mock-TF, HMGB1-TF, and HMGB1-TF plus HMGB1 siRNA-treated KATOIII cells for 24 h. Columns, mean number of HUVECs
migrating through the inserts in three independent experiments, as observed using DP controller software with an IX71 microscope (magnifica-
tion, 9100; Olympus Corporation). Staining, 2 lM calcein AM for 30 min. Bars, SE. *P < 0.05; **P < 0.01, Student’s t-test.
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Fig. 4. In vitro angiogenesis assay in gastric cancer cell lines: HUVEC capillary tube formation assay. (a) Capillary tube formation activity of
HUVECs cultured in conditioned medium (CM) derived from untreated, 10 lg/mL recombinant human high-mobility group box-1 (rhHMGB1)-
treated, or 10 lg/mL rhHMGB1 plus 60 lg/mL anti-HMGB1 antibody (Ab)-treated N87 cells for 24 h. (b) Tube formation activity of HUVECs cul-
tured in CM derived from mock-transfected (TF), HMGB1-TF, or HMGB1-TF plus HMGB1 siRNA-treated N87 cells for 24 h. (c) Tube formation
activity of HUVECs cultured in CM derived from rhHMGB1-treated KATOIII cells. (d) Tube formation activity of HUVECs cultured in CM derived
from HMGB1-TF KATOIII cells. Columns, mean counts of tube formation in three independent experiments (left). Bars, SE. *P < 0.05; **P < 0.01,
Student’s t-test. Images are obtained using DP controller software with an IX71 microscope (Olympus Corporation) (magnification, 940; right).
Staining, 2 lM calcein AM for 30 min.
Fig. 5. Linear regression graphs presenting the correlation between serum high-mobility group box-1 (HMGB1) levels and serum cyokines/
chemokines levels in gastric cancer. The graphs show the positive correlations of serum HMGB1 levels with serum interleukin-8 (IL-8), vascular
endothelial growth factor (VEGF), and tumor necrosis factor-a (TNF-a) levels. Among them, serum IL-8 levels show the strongest correlation with
serum HMGB1 levels.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Similarly, HUVECs cultured in CM derived from HMGB1-TF
N87 and KATOIII cells showed higher capillary tube forma-
tion activities than HUVECs cultured in CM derived from
mock-TF N87 and KATOIII cells (P < 0.05 for all; Fig. 4b,d).
Overall, these results confirm that overexpressed extracellular
HMGB1 contributes to tumor angiogenesis in GC cells
in vitro.
Interleukin-8 mediates HMGB1-induced tumor angiogene-
sis. Many tumor-derived soluble factors are involved in the
complex regulation of tumor angiogenesis. To determine which
soluble factors mediate HMGB1-induced tumor angiogenesis,
we evaluated serum levels of 20 cytokines/chemokines that are
known to be involved in GC progression by chemiluminescent
immunoassays using 120 GC serum samples. Of the examined
cytokines/chemokines, serum levels of IL-8 (R = 0.496,
P < 0.001), tumor necrosis factor-a (R = 0.277, P = 0.020),
and VEGF (R = 0.189, P = 0.036) were significantly corre-
lated with serum HMGB1 levels (linear regression; Fig. 5).
Among these, IL-8 was the cytokine most significantly corre-
lated with serum HMGB1.
Because serum IL-8 showed the strongest correlation with
serum HMGB1 among the examined cytokines/chemokines
(P < 0.001), and is a well-known pro-angiogenic factor in can-
cers,(23,24) IL-8 may be an essential tumor-derived soluble fac-
tor that mediates HMGB1-induced tumor angiogenesis in GC.
To confirm our hypothesis, we examined whether the enhance-
ment of rhHMGB1-induced or HMGB1-TF-induced HUVEC
migration or tube formation activities can be abrogated by
IL-8 inhibition. To prepare CM for this experiment, GC cells
were cultured in RPMI-1640 supplemented with 1% FBS and
rhHMGB1 (10 lg/mL) for 72 h with or without pretreatment
of IL-8 siRNA, and the resultant culture medium was
Fig. 6. In vitro angiogenesis assays showing that interleukin-8 (IL-8) mediates high-mobility group box-1 (HMGB1)-induced tumor angiogenesis
in gastric cancer cells. (a, b) HUVEC migration assay. (a) Significant decline in the migratory activity of HUVECs cultured in CM derived from recom-
binant human HMGB1 (rhHMGB1; 10 lg/mL) plus IL-8 siRNA-treated N87 cells compared with that of HUVECs cultured in CM derived from cells
treated with rhHMGB1 alone. (b) Significant decline in the migratory activity of HUVECs cultured in CM derived from HMGB1-transfected
(HMGB1-TF) plus IL-8 siRNA-treated N87 cells compared with that of HUVECs cultured in CM derived from cells treated with HMGB1-TF alone.
(c, d) HUVEC capillary tube formation assay. (c) Significant decline in tube formation activity of HUVECs cultured in CM derived from rhHMGB1
plus IL-8 siRNA-treated or HMGB1-TF plus IL-8 siRNA-treated N87 cells compared with that of HUVECs cultured in CM derived from rhHMGB1-trea-
ted or HMGB1-TF N87 cells (upper panel). Decline in tube formation activity of HUVECs cultured in CM derived from KATOIII cells in which IL-8
was inhibited by IL-8 siRNA (lower panel). (d) Images of capillary tube formation of HUVECs obtained using DP controller software with an IX71
microscope (magnification, 940; Olympus Corporation). Columns, mean of three experiments. Bars, SE. *P < 0.05; **P < 0.01, Student’s t-test.
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collected. The collected medium was centrifuged, obtained as
the supernatant, and used as CM. Similarly, HMGB1-TF GC
cells were cultured in RPMI-1640 supplemented with 1% FBS
for 72 h with or without pretreatment of IL-8 siRNA, and the
resultant culture medium was collected for CM preparation.
As expected, the migration activity of HUVECs cultured in
CM derived from GC cells treated with both rhHMGB1 and
IL-8 siRNA was remarkably reduced compared with that of
HUVECs cultured in CM derived from GC cells treated with
rhHMGB1 alone (Fig. 6a). Similarily, the enhancement of
migration activity of HUVECs by HMGB1-TF was abrogated
by pretreatment of IL-8 siRNA (Fig. 6b).
The enhancement of capillary-like tube formation activity of
HUVECs by rhHMGB1-treatment or HMGB1-TF was also
abrogated by pretreatment with IL-8 siRNA (Fig. 6c,d). Taken
together, our findings indicate that IL-8 mediates extracellular
HMGB1-induced tumor angiogenesis in GC.
Discussion
High-mobility group box-1, originally known as a nuclear pro-
tein, acts as a crucial pro-inflammatory cytokine in its secre-
tory form.(15,16) Recent studies have shown that overexpressed
extracellular HMGB1 contributes to cancer carinogenesis and
metastasis by promoting apoptotic evasion, mediating tumor-
associated inflammation, and promoting tumor cell migration
and angiogenesis.(15–18) However, the exact role of overex-
pressed extracellular HMGB1 in cancer progression is still
under investigation.
Because HMGB1 belongs to the high-mobility group super-
family, this protein is expected to contribute to angiogenesis in
various situations, including cancers. Many recent studies have
shown that HMGB1 is involved in tumor angiogenesis in sev-
eral cancers.(17,18) Previously, we showed that high levels of
serum HMGB1 are closely correlated with GC progression in
GC patients from the pre-invasive stage.(20) We also reported
that overexpressed extracellular HMGB1 induced EMT, a criti-
cal process for metastasis initiation, under overxpressed IL-8
mediation in GC.(25) Interleukin-8 is also a well-known angio-
genic and tumor aggravation factor in many cancers, including
GC.(23,24,26,27) Because both HMGB1 and IL-8 contribute to
tumor angiogensis in many cancers, and angiogenesis may be
necessary at any stage during cancer progression,(28) it is possi-
ble that interaction between HMGB1 and IL-8 may contribute
to GC progression by inducing tumor angiogenesis as well as
inducing EMT(25) from the relatively early steps of metastasis.
Therefore, we investigated whether overexpressed extracellular
HMGB1 contributes to tumor angiogenesis in GC with IL-8
mediation in the present study.
To prove our hypothesis, we first showed that overexpressed
extracellular HMGB1 contributes to tumor angiogenesis in GC
by showing a positive correlation between serum HMGB1
levels and MVD in GC tissues clinically (Fig. 2), and by
showing the enhancement of HUVEC migration and tube for-
mation activities through culturing HUVECs in CM derived
from rhHMGB1-treated or HMGB1-TF GC cells in vitro
(Figs. 3,4). These findings indicate that extracellular HMGB1
overexpression contributes to tumor angiogenesis in GC. Next,
we analyzed 20 GC-related cytokines/chemokines using 120
GC serum samples to determine soluble factors involved in
HMGB1-induced tumor angiogenesis. We found that IL-8 was
the cytokine/chemokine most significantly correlated with
serum HMGB1 (R = 0.496, P < 0.001; Fig. 5). This agreed
with results reported in our previous study,(25) in which inde-
pendent GC serum samples and a different cytokine panel
were used. Finally, we found that IL-8 inhibition suppressed
the overexpressed HMGB1-induced increase in HUVEC
migration and tube formation activities (Fig. 6). Collectively,
we showed that overexpressed extracellular HMGB1 can
induce tumor angiogenesis in GC, and IL-8 might mediate this
process.
Interaction between VEGF-A and the VEGF receptor-1 or -2
axis is a key process for blood vessel growth.(4) In the current
study, we observed that VEGF levels were also correlated with
serum HMGB1 levels. This result may suggest that VEGF is
also involved in HMGB1-induced tumor angiogenesis.
Fig. 7. Schematic figure of a hypothetic model of interaction between extracellular high-mobility group box-1 (HMGB1) and interleukin-8 (IL-8)
during gastric cancer (GC) progression. This interaction may contribute to GC progression at a relatively early stage of GC metastasis, providing a
mechanistic link between tumor angiogenesis and epithelial–mesenchymal transition (EMT) through HMGB1 and IL-8 interaction. AGC-M0,
locally advanced GC without metastasis. AGC-M1, highly advanced GC with metastasis. EGC, early GC; TNF-a, tumor necrosis factor-a.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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However, we did not evaluate the effects of VEGF in the cur-
rent study because the degree of correlation of this cytokine
with serum HMGB1 was not significantly higher (R = 0.189,
P = 0.036) than that of IL-8 (Fig. 5). Thus, VEGF may not be
a major soluble mediator involved in the HMGB1-induced
tumor angiogenesis. Instead, it is possible that VEGF may be
involved in HMGB1-induced tumor angiogenesis indirectly
through connection with IL-8, similar to the results reported in
several previous studies.(23,28) However, further additional
studies are needed to confirm this.
Another previous study co-cultured HUVECs with GC cells
directly to access in vitro angiogenesis.(23) However, we cultured
HUVECs in CM derived from rhHMGB1-treated or HMGB1-
TF GC cells instead of co-culturing with GC cells to exclude
interference of factors other than overexpressed HMGB1.
For in vitro experiments, we used two different histological
types of GC cell lines, namely, N87, a well-differentiated ade-
nocarcinoma cell line, and KATOIII, a signet-ring cell carci-
noma cell line, because these two cell lines have different
clinicopathological features. However, the effect of overex-
pressed extracellular HMGB1 on tumor angiogenesis was not
significantly different between the two cell lines (Figs. 3,4,6).
In summary, the results of the present study indicate that
overexpressed extracellular HMGB1 promotes tumor angiogen-
esis under IL-8 mediation in GC. To our knowledge, this is
the first study to show that HMGB1 contributes to tumor
angiogenesis in GC and this process is associated with IL-8. In
addition, the results of our previous(25) and current study sug-
gest a model of interaction in which extracellular HMGB1 and
IL-8 may contribute to GC progression, providing a mechanis-
tic link between tumor angiogenesis and EMT at a relatively
early stage of GC metastasis (Fig. 7). That is, high levels of
HMGB1 may increase the recurrence and metastasis of GC by
facilitating easy dissemination of cancer cells in circulation
through both EMT induction and tumor angiogenesis, and IL-8
is the major HMGB1-associated soluble mediator that partici-
pates in these two processes simultaneously during GC pro-
gression (Fig. 7).
In conclusion, results of the present study suggest the poten-
tial efficacy of combined targeting of HMGB1 and IL-8 for
controlling tumor angiogenesis and ultimately improving the
poor prognosis of patients with GC. We believe that our find-
ings provide important clues on the mechanisms underlying
the high rate of recurrence and metastasis of GC, and could
help in developing a new promising therapeutic strategy for
GC.
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